The promise of CELMoDs in myeloma treatment
The speakers highlighted how combining these powerful drugs into fixed-duration regimens could help patients achieve long-term remissions and move closer to a cure.
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
EHA. 2026 updates on the phase 3 MajesTEC-3 trial and MonumenTAL-3 trials
The panel also discussed the success of combining teclistamab and daratumumab for functional high-risk patients who historically experience poor outcomes.
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
How can trispecifics be integrated with CELMoDs in myeloma treatment?
The panel discussed combining trispecifics with mezigdomide, noting the strong activity and improved tolerability of targeting BCMA and CD38. They also discussed how
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Intergrating CELMoDs with other therapies in myeloma
The panel also discussed the therapeutic potential of these combinations. Dr. Banerjee highlighted the role of CELMoDs in post-CAR T care, noting that
ASCO 2026
Trending now
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
Video Interviews
Andrew Kuykendall, MD, discusses updated data from the RALLY-MF trial
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974
ASCO 2026
Meetings / Conferences
Myeloproliferative Neoplasms
News
Selinexor plus ruxolitinib meaningfully improved spleen response in MF trial
In this video from the 2026 ASCO Annual Meeting, Dr. Mascarenhas, a Professor of Medicine at the Icahn School of Medicine at Mount
Focus on CELMoDs
EHA 2026
Meetings / Conferences
Multiple Myeloma
Roundtable Discussions
Video Interviews
Survivorship details from the SUCCESOR-2 trial
Dr. Banerjee reviewed the BCMA-sparing clinical efficacy data from the trial and discussed the results, which showed that MeziKd significantly extended progression-free survival
EHA 2026
Meetings / Conferences
Myeloproliferative Neoplasms
Primary Myelofibrosis
Dr. Naseema Gangat discusses initial data from RALLY-MF trial
In this interview from the 2026 European Hematology Association Congress, Naseema Gangat, MBBS, a professor of medicine at the Mayo Clinic in Rochester,
Lymphoma
Indolent B-Cell Lymphomas
EC grants marketing authorization to epcoritamab combo in second-line FL
The European Commission has granted marketing authorization to epcoritamab (TEPKINLY® ) in combination with rituximab and lenalidomide (R2) for the treatment of relapsed or
EHA 2026
Meetings / Conferences
EHA 2026: Nipocalimab shows promise in rare anemia
Warm autoimmune hemolytic anemia is a rare disease with no current approved therapy. In the trial, the investigators reported that nipocalimab had durable